Holen Sie sich die Stockscreener-App
14.04
4.36%
-0.64
Handel nachbörslich:
13.75
-0.29
-2.07%
Schlusskurs vom Vortag:
$14.68
Offen:
$16.47
24-Stunden-Volumen:
120.25K
Relative Volume:
2.72
Marktkapitalisierung:
$29.26M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-3.34M
KGV:
-5.201
EPS:
-2.6995
Netto-Cashflow:
$-10.54M
1W Leistung:
+5.88%
1M Leistung:
+22.30%
6M Leistung:
-4.42%
1J Leistung:
+51.95%
1-Tages-Spanne:
$13.12
$16.47
1-Wochen-Bereich:
$12.74
$16.47
52-Wochen-Spanne:
$2.88
$18.20
Polyrizon Ltd Stock (PLRZ) Company Profile
Compare PLRZ vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PLRZ
Polyrizon Ltd
|
14.04 | 30.59M | 0 | -3.34M | -10.54M | -2.6995 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Polyrizon Ltd Aktie (PLRZ) Neueste Nachrichten
Polyrizon Ltd (PLRZ) Valuation: PE, PB & Fair Value Analysis - TradingKey
Polyrizon Ltd (PLRZ) Institutional Confidence - TradingKey
Polyrizon Ltd (PLRZ) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Polyrizon Ltd (PLRZ) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Polyrizon Ltd (PLRZ) Balance Sheet - TradingKey
TradingKey - TradingKey
Polyrizon Ltd (PLRZ) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Polyrizon Ltd. Revenue Breakdown – NASDAQ:PLRZ - TradingView
PLRZ|Polyrizon Ltd|Price:13.800|Chg%:-0.880 - TradingKey
Polyrizon Shareholders Approve New Executive Compensation Policy on July 13, 2026 - The Globe and Mail
Polyrizon (PLRZ) locks in 3-year executive and director pay policy - Stock Titan
Polyrizon Ltd. (PLRZ) Rises 2.09% as Shares Approach Resistance at $15.38Cash Secured Put - dars.gov.et
Polyrizon Ltd. (PLRZ) Rallies 7.32% to $15.40 — Bulls Test Key ResistanceDouble Top - DonanımHaber
Polyrizon (PLRZ) Holds Steady Near Support as Stock Edges HigherOption Strike Build - dars.gov.et
Polyrizon retains Nasdaq listing following hearings panel - MSN
Polyrizon Clears Key Safety Milestone for NASARIX Allergy Nasal Spray - TipRanks
Polyrizon (PLRZ) clears NASARIX biocompatibility milestone toward first human trial - Stock Titan
Polyrizon Advances on Test Results - Baystreet.ca
Polyrizon shares climb after NASARIX passes key biocompatibility testing (PLRZ) - Yahoo Finance
Polyrizon completes biocompatibility tests for allergy nasal spray - Investing.com
Polyrizon stock rises on biocompatibility test results By Investing.com - Investing.com Nigeria
Polyrizon completes biocompatibility tests for allergy nasal spray By Investing.com - Investing.com Canada
Polyrizon Announces Successful Results for NASARIX™ Biocompatibility Program, Supporting Advancement Towards First in Human Clinical Trial - The Manila Times
Polyrizon Announces Successful Biocompatibility Results for NASARIX Allergy Blocker Nasal Spray - Quiver Quantitative
Polyrizon’s allergy nasal spray clears safety tests, advancing human trial plans - Stock Titan
Polyrizon's NASARIX nasal spray passes biocompa... - Pluang
Polyrizon Wins Central IRB Nod for First NASARIX Allergy Blocker Trial - TipRanks
[6-K] Polyrizon Ltd. Current Report (Foreign Issuer) | PLRZ SEC FilingForm 6-K - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Polyrizon receives IRB approval for nasal spray clinical trial By Investing.com - Investing.com Nigeria
Polyrizon receives IRB approval for nasal spray clinical trial - Investing.com
Polyrizon Receives Central IRB Approval for First Human Clinical Trial of NASARIX Allergy Blocker - Quiver Quantitative
Polyrizon Makes Strong Progress: Receives Central IRB Approval for its Allergy Blocker Clinical Trial - The Manila Times
Polyrizon clears review to start first NASARIX human allergy trial - Stock Titan
Polyrizon gets IRB approval to start clinical t... - Pluang
Polyrizon (PLRZ) Modestly Gains, Testing Key Resistance ZoneLiquidity Sweep - DonanımHaber
Enterprise value to EBIT forward of Polyrizon Ltd. – NASDAQ:PLRZ - TradingView
Enterprise value to revenue forward of Polyrizon Ltd. – NASDAQ:PLRZ - TradingView
Enterprise value to EBITDA forward of Polyrizon Ltd. – NASDAQ:PLRZ - TradingView
Price to sales forward of Polyrizon Ltd. – NASDAQ:PLRZ - TradingView
Polyrizon receives US patent publication notice for nasal drug delivery platform - MSN
Polyrizon Ltd. Ordinary Shares (NASDAQ: PLRZ) Stock Price, News & Analysis - Kalkine
Polyrizon Ltd. (PLRZ) Inches Higher as Stock Approaches Key Resistance LevelCatalyst Driven Stocks - dars.gov.et
Polyrizon Ltd (PLRZ) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Polyrizon Ltd (PLRZ) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Polyrizon Announces U.S. Publication of Mucoadhesive Nasal Drug Delivery Patent - TipRanks
Polyrizon (Nasdaq: PLRZ) details U.S. patent publication for Trap & Target nasal platform - Stock Titan
Polyrizon announces U.S. patent application publication - Investing.com
Polyrizon Receives Notice of U.S. Patent Publication for Mucoadhesive Drug Delivery Platform - The Manila Times
Polyrizon patent published for nasal drug-delivery technology - Stock Titan
Polyrizon's mucoadhesive nasal drug delivery pa... - Pluang
Finanzdaten der Polyrizon Ltd-Aktie (PLRZ)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):